Trial Profile
Monoinstitutional Phase II Trial Addressing Tolerability and Activity of RCHOP Chemoimmunotherapy Preceded by BBB Permeabilization by t-NGR Necrosis Factor in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2022
Price :
$35
*
At a glance
- Drugs NGR-TNF (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma
- Focus Therapeutic Use
- Acronyms Ingrid
- 02 Aug 2022 Status changed from recruiting to completed.
- 04 Dec 2018 Results (n=22) reporting activity, safety and Blood Brain Barrier permeabilization, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 04 Jun 2018 According to MolMed media release, data from this trial will be presented at ASCO.